{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:29:55Z","timestamp":1762432195858,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ijid.2022.01.051","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T10:21:15Z","timestamp":1643538075000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study"],"prefix":"10.1016","volume":"117","author":[{"given":"Jing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5266-033X","authenticated-orcid":false,"given":"Junyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijid.2022.01.051_bib0001","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/FTD.0000000000000443","article-title":"Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants","volume":"39","author":"Bednasz","year":"2017","journal-title":"Therapeutic drug monitoring"},{"issue":"3","key":"10.1016\/j.ijid.2022.01.051_bib0002","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000002067","article-title":"Randomized clinical trial on efficacy of fixed-dose efavirenz\/tenofovir\/emtricitabine on alternate days versus continuous treatment","volume":"33","author":"Bellagamba","year":"2019","journal-title":"AIDS (London, England)"},{"issue":"7","key":"10.1016\/j.ijid.2022.01.051_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071687","article-title":"NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved","volume":"10","author":"Benedicto","year":"2021","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.ijid.2022.01.051_bib0004","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","article-title":"Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients","volume":"76","author":"Ciccarelli","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ijid.2022.01.051_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/infdis\/jiaa373","article-title":"Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy","volume":"223","author":"Cyktor","year":"2021","journal-title":"The Journal of infectious diseases"},{"year":"2021","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","key":"10.1016\/j.ijid.2022.01.051_bib0006"},{"key":"10.1016\/j.ijid.2022.01.051_bib0007","unstructured":"Division of AIDS (DAIDS)table for grading the severity of adult and pediatric adverse events. Version 2.0. (2014). National Institute for Allergy and Infectious Diseases. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daids-ae-grading-table-v2-nov2014.pdf."},{"key":"10.1016\/j.ijid.2022.01.051_bib0008","unstructured":"EACS Guidelines Version 10.1. October2020. https:\/\/www.eacsociety.org\/guidelines\/Details.from-version-9.1to10"},{"issue":"2","key":"10.1016\/j.ijid.2022.01.051_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3851\/IMP3188","article-title":"3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz\/emtricitabine\/tenofovir and rilpivirine\/emtricitabine\/tenofovir","volume":"23","author":"Gagliardini","year":"2018","journal-title":"Antiviral therapy"},{"issue":"9","key":"10.1016\/j.ijid.2022.01.051_bib0010","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/QAD.0000000000002908","article-title":"Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen","volume":"35","author":"Gianotti","year":"2021","journal-title":"AIDS (London, England)"},{"issue":"11","key":"10.1016\/j.ijid.2022.01.051_bib0011","doi-asserted-by":"crossref","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","article-title":"CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz","volume":"73","author":"Griesel","year":"2021","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"9927","key":"10.1016\/j.ijid.2022.01.051_bib0012","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"Group","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ijid.2022.01.051_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/hiv.12607","article-title":"Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study","author":"Guo","year":"2018","journal-title":"HIV medicine"},{"issue":"11","key":"10.1016\/j.ijid.2022.01.051_bib0014","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Guti\u00e9rrez","year":"2005","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"2","key":"10.1016\/j.ijid.2022.01.051_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148915","article-title":"The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014","volume":"11","author":"He","year":"2016","journal-title":"PloS one"},{"key":"10.1016\/j.ijid.2022.01.051_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.579448","article-title":"Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Na\u00efve HIV-Infected Patients in China: A Prospective Cohort Study","volume":"12","author":"Hua","year":"2021","journal-title":"Frontiers in psychiatry"},{"key":"10.1016\/j.ijid.2022.01.051_bib0017","unstructured":"Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry. (2015). US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/media\/86284\/download"},{"issue":"8","key":"10.1016\/j.ijid.2022.01.051_bib0018","first-page":"331","article-title":"Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV","volume":"12","author":"Katsounas","year":"2007","journal-title":"European journal of medical research"},{"issue":"6","key":"10.1016\/j.ijid.2022.01.051_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130583","article-title":"Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection","volume":"10","author":"Meng","year":"2015","journal-title":"PloS one"},{"issue":"3","key":"10.1016\/j.ijid.2022.01.051_bib0021","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1086\/510746","article-title":"CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression","volume":"44","author":"Moore","year":"2007","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.ijid.2022.01.051_bib0022","unstructured":"National Handbook of Free Antiretroviral Therapy Treatment, 4th ed. (2016). http:\/\/www.sxcdc.com\/uploadfiles\/files\/2017071711372183.pdf"},{"issue":"5","key":"10.1016\/j.ijid.2022.01.051_bib0023","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2125.2006.02619.x","article-title":"Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients","volume":"61","author":"Pereira","year":"2006","journal-title":"British journal of clinical pharmacology"},{"issue":"11","key":"10.1016\/j.ijid.2022.01.051_bib0024","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/jac\/dkr360","article-title":"Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals","volume":"66","author":"Poeta","year":"2011","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"3","key":"10.1016\/j.ijid.2022.01.051_bib0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/09540121.2016.1201194","article-title":"Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand","volume":"29","author":"Prasithsirikul","year":"2017","journal-title":"AIDS care"},{"issue":"12 Suppl","key":"10.1016\/j.ijid.2022.01.051_bib0027","first-page":"s231","article-title":"The importance of treatment adherence in HIV","volume":"19","author":"Schaecher","year":"2013","journal-title":"The American journal of managed care"},{"key":"10.1016\/j.ijid.2022.01.051_bib0028","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/PPA.S31385","article-title":"Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era","volume":"6","author":"Sterrantino","year":"2012","journal-title":"Patient preference and adherence"},{"issue":"8","key":"10.1016\/j.ijid.2022.01.051_bib0029","first-page":"9","article-title":"Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART","author":"Vera","year":"2019","journal-title":"Brain sciences"},{"issue":"1","key":"10.1016\/j.ijid.2022.01.051_bib0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12955-017-0731-8","article-title":"Health-related quality of life in pregnant women living with HIV: a comparison of EQ-5D and SF-12","volume":"15","author":"Wang","year":"2017","journal-title":"Health and Quality of Life Outcomes"},{"issue":"1","key":"10.1016\/j.ijid.2022.01.051_bib0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12879-021-05802-8","article-title":"Pharmacodynamics of efavirenz 400 mg in treatment-na\u00efve Chinese HIV-infected patients in a prospective cohort study","volume":"21","author":"Xu","year":"2021","journal-title":"BMC infectious diseases"},{"key":"10.1016\/j.ijid.2022.01.051_bib0032","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3389\/fimmu.2020.01541","article-title":"HIV Reservoir Decay and CD4 Recovery Associated With High CD8 Counts in Immune Restored Patients on Long-Term ART","volume":"11","author":"Zhang","year":"2020","journal-title":"Frontiers in immunology"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222000595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222000595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:05:13Z","timestamp":1761120313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222000595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":30,"alternative-id":["S1201971222000595"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.01.051","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.01.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}